In a natural experiment involving 72,920 propensity-matched US adults aged 60 years and older, recombinant shingles vaccination was associated with a 9% lower cardiovascular disease burden over seven years compared with the live attenuated vaccine. Lower burdens of ischemic heart disease and heart failure were seen in both sexes, while ischemic stroke was significantly lower only among men, supporting further clinical trials and mechanistic studies
